

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
18 August 2022 (18.08.2022)



(10) International Publication Number
WO 2022/174000 A3

(51) International Patent Classification:

C12N 15/113 (2010.01) A61P 25/28 (2006.01)
A61K 31/713 (2006.01)

(21) International Application Number:

PCT/US2022/016046

(22) International Filing Date:

11 February 2022 (11.02.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/148,991 12 February 2021 (12.02.2021) US
63/270,176 21 October 2021 (21.10.2021) US

(71) Applicant: ALNYLAM PHARMACEUTICALS, INC.
[US/US]; 675 West Kendall Street, Henri A. Termeer
Square, Cambridge, MA 02142 (US).

(72) Inventors: CASTORENO, Adam; 675 West Kendall
Street, Henri A. Termeer Square, Cambridge, MA 02142
(US). GILBERT, Jason; 675 West Kendall Street, Hen-
ri A. Termeer Square, Cambridge, MA 02142 (US).
KAITTANIS, Charalambos; 675 West Kendall Street,
Henri A. Termeer Square, Cambridge, MA 02142 (US).
MCININCH, James, D.; 675 West Kendall Street, Hen-
ri A. Termeer Square, Cambridge, MA 02142 (US).
MILSTEIN, Stuart; 675 West Kendall Street, Henri
A. Termeer Square, Cambridge, MA 02142 (US). SCH-
LEGEL, Mark, K.; 675 West Kendall Street, Henri A. Ter-
meer Square, Cambridge, MA 02142 (US).

(74) Agent: ZACHARAKIS, Maria, Laccotripe et al.; Mc-
Carter & English, LLP, 265 Franklin Street, Boston, MA
02110 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JM, JO, JP, KE, KG, KH,
KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA,
MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI,
NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU,
RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM,
ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,

GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a
patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the
earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

(88) Date of publication of the international search report:

13 October 2022 (13.10.2022)

(54) Title: SUPEROXIDE DISMUTASE 1 (SOD1) IRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING
OR PREVENTING SUPEROXIDE DISMUTASE 1- (SOD1-) ASSOCIATED NEURODEGENERATIVE DISEASES

(57) Abstract: The disclosure relates to double stranded ribonucleic acid (dsRNAi) agents and compositions targeting a SOD1 gene,
as well as methods of inhibiting expression of a SOD1 gene and methods of treating subjects having a SOD1-associated neurodegen-
erative disease or disorder, e.g. Amyotrophic Lateral Sclerosis (ALS), Alzheimer's disease (AD), Parkinson's disease (PD) and Down's
syndrome (DS), using such dsRNAi agents and compositions.



WO 2022/174000 A3